Understanding the Impact of COSMIC-311 and Sequencing in DTC

Marcia Brose, MD, examines data from the COSMIC-311 study, emphasizing the importance of promptly initiating second-line therapy for patients who have progressed on first-line treatments.

Related Keywords

,Optimizing Therapy ,Kbraf ,Cosmic 311 ,Lenvatinib ,Sorafenib ,Cabozantinib ,Braf Mutations ,Vegf ,Braf Inhibitor ,Braf V600e ,Tumor Shrinkage ,Ocular Toxicities ,Cardiac Toxicities ,